Thus, the aim of our present study was (i) to provide serum ZAG profiles in three different groups (NW + CRC patients, OW/OB + CRC patients, and healthy controls); (ii) to investigate the mRNA expressions of ZAG in sWAT and vWAT in NW + CRC and OB + CRC patients; and (iii) to assess the association between circulating ZAG concentrations and the risk of CRC. This evidence concerns the gene AZGP1 and colorectal carcinoma.